Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Phase II Study of Pembrolizumab Plus Lenvatinib in Patients With Unresectable Cutaneous Angiosarcoma

NCT06673628 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT06673628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06673628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Phase II Study of Pembrolizumab Plus Lenvatinib in Patients With Unresectable Cutaneous Angiosarcoma
Lead sponsor
National Cancer Center, Japan
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2024
Completion date
November 30, 2029
Enrollment
38 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma metastatic, angiosarcoma of skin